Cargando…
Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies
Recipients of solid organ transplants (SOT) are at higher risk of infection by SARS-CoV-2 virus especially due to chronic immunosuppression therapy and frequent multiple comorbid conditions. COVID-19 is a potentially life-threatening disease in SOT recipients, with an increased likelihood of progres...
Autores principales: | Candel, Francisco Javier, Salavert, Miguel, Mingot, David Lorite, Crespo, Marta Manzano, Portero, Paula Pérez, Pinto, Rafael Cuervo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336315/ https://www.ncbi.nlm.nih.gov/pubmed/37089055 http://dx.doi.org/10.37201/req/023.2023 |
Ejemplares similares
-
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant
Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021) -
479. Real-world Evaluation of SARS-CoV-2 Monoclonal Antibodies in Solid Organ Transplant Recipients
por: Zeitler, Kristen, et al.
Publicado: (2021) -
465. Use of Monoclonal Antibodies for COVID-19 in Solid Organ Transplant Recipients: A Single-Center Experience
por: Gomez, Keven, et al.
Publicado: (2023) -
True effect of monoclonal antibody for COVID-19 in kidney transplant recipients
por: Khatri, Akshay, et al.
Publicado: (2022) -
Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)